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ABSTRACT 
Objective: To calculate the direct medical and non-medical cost, indirect non-medical cost of prescription involved in the treatment of hypertension 
in rural inpatients at tertiary care teaching hospital.  
Methods: A cross sectional, prospective and patient based cost of illness study was conducted in tertiary care hospital, Chidambaram for 12 mo and 
267 new prescriptions was selected for the analysis. The data collected from the prescription included patient’s socio-demographics, hypertension 
stage, drug therapy consumption, anti-hypertensive category and cost of each drug. Drug procurement costs were calculated, by using the TNG 
medical supply list of the most commonly prescribed drugs, for each drug on a daily and annual basis.  
Results: Mean patient age were 60.6±10.5 y. 41.9% patients were having prevalence of hypertension at the age of above 60 y, 52.8% were males 
and 47.2% were females. The mean (systolic/diastolic) blood pressure was 141.8 mmHg (±15.2). Average annual direct medical costs were found to 
be 1T₹1T ,408,082.4, average annual direct non-medical cost was 1T₹1T9171.4 and the average annual indirect non-medical costs incurred by productivity 
loss were 1T₹ 1T 0789.2.  
Conclusions: Direct and indirect non-medical costs have incurred high when compared with the other costs. The annual average total direct 
(medical and non-medical) costs per patient and total cost of illness were 1T₹1T ,417,253.8 and 1T₹1T27,993,470.0 respectively. 
Keywords: Cost-of-illness, Hypertension, Therapy consumption, Direct medical and non-medical cost, Indirect non-medical cost and morbidity cost 
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INTRODUCTION 
Hypertension is a major health threatening problem. The prevalence 
of hypertension is predicted to be 60% increase from 26.4% in 2000 
to 29.2% in 2025 throughout the globe [1]. This is one of the leading 
causes of death and disability, particularly in developing countries. 
The hypertension may lead to following complications: 
cardiovascular diseases (CVD), diabetes mellitus, unstable angina, 
myocardial infarction (MI), dilated cardiomyopathy (DCM), diabetic 
foot ulcer, diabetic retinopathy, hypertensive retinopathy, unstable 
angina, hypothyroidism and hyperthyroidism. Among them CVD is a 
majority and projected to cause 4.6 million deaths in India by 2020. 
There are many studies reported the incidence of hypertension.  
In India one of the study reported the average prevalence of 
hypertension is ranging from 10 to 30.9%. Another study has stated the 
prevalence is 25% and 10% in urban and rural inhabitants respectively 
[2]. The therapeutic goal of the hypertension treatment is to reduce the 
blood pressure and to control its associated comorbidities with 
appropriate selection of drug and/or lifestyle modifications [3]. The 
WHO and the European society of hypertension recognize that the early 
death and disability caused by cardiovascular disease is a big economic 
burden for any country, but could be solved by preventive measures, 
particularly through better control of hypertension [4].  
“Pharmacoeconomics (PE) is an established sub-discipline of health 
economics concerned with the evaluation of pharmaceutical 
products in terms of their value for money [5]. Pharmacoeconomics 
has been defined as the description and analysis of the cost of drug 
therapy to healthcare systems and society and research is the 
process of identifying, measuring, and comparing the costs, i.e., risks, 
and benefits of programs, services, or therapies and determining 
which the best alternate produces the best health outcome for the 
resource invested. The economic evaluation methodologies or tools 
can be separated into two major components: Economic and 
humanistic evaluation methods. Different economic evaluation 
techniques are cost benefit analysis (CBA), cost effectiveness 
analysis (CEA), cost minimization analysis (CMA), cost utility 
analysis (CUA) and cost of illness (COI). Cost of illness (COI) is used to 
identify and calculate the overall expenditure incurred to treat the 
disease and it may be calculated per person per annum. The unit of 
outcome for these studies will be expressed in terms of Indian rupees 
(INR). The COI involves two types’ of components they are (i) Cost (ii) 
Consequences. Cost is defined as the value of financial resources 
incurred to treat the medical condition. A consequence is measured 
effects, outputs, or outcomes of the drug therapy of interest [6].  
The health economics include three major components: (i) Direct 
medical and non medical cost (ii) Indirect non medical cost (iii) 
Intangible cost. The Direct medical cost includes drugs, medical 
supplies, and equipment, laboratory and diagnostic tests, 
hospitalizations, and physician visits. Direct nonmedical costs are 
any costs for services that are results of illness or disease, but do not 
involve purchasing the medical services and includes transportation, 
food, family care and home aides and whereas the indirect non 
medical costs includes lost wages (morbidity) and income forgone 
because of premature death (mortality). Direct non-medical cost is 
incurred to receive services other than medical care and it includes 
the amount spent by patients for transportation to and from 
healthcare facilities, extra trips to the emergency department, child 
or family care expenses, special diets, and various other out-of-
pocket expenses. Indirect non-medical costs are the costs of reduced 
productivity (e. g., morbidity and mortality costs) and third category, 
the intangible cost of pain and grief, is often unquantifiable [6]. In 
this present study, the intangible cost due to hypertension is not 
received. The aim of the present study is to determine the cost 
involved in the treatment of hypertensive patients admitted in a 
tertiary care teaching hospital located in a rural part of South India. 
MATERIALS AND METHODS 
Study site 
The study was conducted at a tertiary care teaching hospital having 
1260 beds situated in Cuddalore District, Tamil Nadu, and South India.  
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Study design 
Prospective, cross sectional, patient and hospital based cost of 
illness survey 
Study perspective 
Patient and provider perspective 
Study duration and period 




1. Inpatients only 
2. Patients prescribed with at least one antihypertensive 
medication. 
3. Patients suffering from hypertension with or without multiple 
concomitant diseases like diabetes mellitus, hyperlipidemia, 
diabetic retinopathy, hypothyroidism, bronchial asthma, 
hypertensive retinopathy, CVA hemiplegia, unstable angina, 
tuberculosis, hypertensive nephropathy. 
4. Patients are having ≥ 35 y, both the genders. 
5. Patients who were willing to participate and provide informed 
consent form. 
6. Patients suffering from hypertension more than three months. 
Exclusion criteria 
1. Outpatients only 
2. A Patient who had discontinued the treatment for more than 3 d. 
3. Patients who were having any form of induced hypertension 
like eclampsia. 
4. Patients who were not willing to provide informed consent 
form. 
Among 267 patients cross sectional survey was conducted and data 
were collected in a standard proforma. Direct cost was estimated by 
bottom-up technique and indirect cost was estimated by Human 
capital method. Informed consent form was obtained prior to start 
the study.  
Ethical considerations 
The study protocol was approved by the Institutional Human Ethical 
Committee of the hospital (Approval No.: M18/RMMC/2013). 
Collection of data 
292 patients were enrolled in the study. Among them, 25 patients 
were identified dropouts from the present study. Out of 25 patients, 
12 patients were informed they were shifted their place of living. 2 
patients were not willing to participate, 2 patients were without 
informing the reason they were discontinued study and 9 patients 
were lost to follow up. A proforma was prepared and tested with a 
small group of the study population. By using this proforma and data 
were collected from the registered patients.  
Study proforma contains 3 domains: (i) Socio demographic features, 
which contains 12 parameters were age, gender, date of visit, 
number of visits, risk factors, population of living status, economic 
status, duration of hospital stay, qualification, yearly estimate 
household income, knowledge and awareness on hypertension and 
occupational status (ii) clinical features, which contains 5 
parameters were systolic and diastolic pressure, drugs prescribed, 
poly pharmacy, therapy duration, hypertension with major/minor 
vascular complications (iii) monetary features, which contains drug 
cost, transportation cost, equipment and diet cost, medical supplies, 
diagnostic/laboratory cost, hospitalization cost and personnel cost. 
Pharmacoeconomic evaluation study was based on data collected 
through face to face interaction with patients in the general 
medicine ward for the duration of 12 mo diagnosis.  
Study methods 
Therapy consumption cost 
Therapy consumption was based on cost per defined daily dose 
(C/DDD) in metric units [7]. All the costs were expressed in Indian 
rupees (INR) for the year of (2014–2015) throughout the study 
period. The DDD was used to calculate the medication cost. 
Direct costs 
Total direct costs = Total direct medical cost+Total direct non-
medical cost.  
Direct medical cost 
In this study, the direct medical cost calculated consisted of the cost 
of medication, medical supplies cost, personnel cost, cost of 
diagnostic/laboratories and hospitalization cost. 
Direct non-medical cost 
Expenditure for incurred transportations by each patient during 
every hospital visits using Tamil Nadu Road Transport (TRT). 
Transportation cost 1km = 
The cost of hospitalization included registration (prescription) cost 
(
₹0.50 paisa.  
Direct medical and non-medical cost computational study 
Fixed cost 
For estimating the equipment cost and diet costs were incurred by 
the hospital for providing the service. 
Equipment cost 
Equipment costs included the unit cost of Electrocardiogram (ECG), 
Echocardiogram (Echo) and Treadmill costs were collected from 
Coronary cardiac Unit (CCU). Estimating the cost of equipment 
received by the hospital for furnishing the service to the patient.  
Diet cost 
Diet cost was obtained from the hospital for the year [2014–2015].  
Variable cost 
Medication cost 
Total medication cost = C/DDD X Number of patients involved X 365 d.  
All prescribed drugs were rendering to the patient according Tamil 
Nadu Standard Treatment Guidelines (TNSTG) guidelines and 
hospital drug list. 
Free cost components  
Some drugs were furnished at free of cost to the patient by the 
hospital. 
Medical supplies cost 
Medical supplies cost includes sample (blood) collection tube; 
syringes, intravenous sets, needles, sutures, bandage, and sterile 
water for injection were calculated. 
Diagnostic/laboratory cost 
The diagnostic test cost is the sum of cost of Electro cardiogram, 
Echocardiogram and X-ray and blood glucose test, electrolytes test, 
lipid profiles, blood transfusion, thyroid–stimulating hormone (TSH) 
test were derived based upon the interviews with patients and from 
their records of the pharmacy.  
Hospitalization cost 
₹ 2.00/patient), admission cost (₹ 40.00/patient), staying charges 
per day, food items and drinks, other items were computed in 
relation to patients who needed hospitalization for diagnosis and 
treatment of hypertension. The hospitalization costs were collected 
from the first day of admission to discharge from the hospital.  
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Table 1: Data on socio demographic and clinical features of hypertensive patients with or without multiple comorbidities (N = 267) 
Sociodemographical features Number of patients (%) 
N = 267 (%) Male (N = 185)  Female (N = 82)  
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≥ 10 d 
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Primary (1-5th




















Yearly estimate household income (INR) [ Min–
Max] 
Mean 
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Blood pressure classification based JNC VII    
120–139/80-89 [Pre hypertension] 
140–159/90-99 [Stage 1 hypertension] 


















≥ 8 drugs 190 (71.1%) 134 (72.4%) 56 (68.3%) 
Drugs prescribed    
Single therapy  
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 CAD: Coronary Artery Diseases; MI: Myocardial Infarction; DCM: Dilated Cardiomyopathy; INR: Indian Rupees (
 
₹); N: Number of patients 
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Patient (personnel) cost 
The hospital doesn’t charge for physician visit every day. 
Estimation of indirect non-medical cost 
Indirect costs were associated the income or absenteeism from 
work (lost productivity) estimated by the human capital approach 
[8] was categorized into two categories: morbidity cost and 
mortality cost.  
Measurement of morbidity cost 
Morbidity costs are costs incurred for missing work (i.e., lost 
productivity). It was computed by multiplying the total number of 
days taken off due to hypertension for both the patient and family 
members, by the average gross earning per day per person in 
2015, with the actual wage rate of the patient. Income data were 
observed from the admission slip in the patient’s case sheets. In 
this study the method was utilized self-reported average wage 
rate. Daily loss of productivity was measured either by assuming 
age-specific wage or an occupation-specific wage applied in other 
studies.  
Analysis of total annual cost of illness 
Total annual cost of illness = Total direct cost of illness+Total 
indirect cost of illness 
RESULTS 
Socio demographic characteristics 
Registered 267 patients were given their consent and participated in 
the present study and overall response rate is 91.4%. Among 267 
patients, 69.3% were males and 30.7% were females in the study 
group. The average age of male and female patients was found to be 
62.6 and 60.4 y respectively.  
The higher number of hypertensive patients was observed in the 
age group of 55–75 y, 56.2%, 62.2% were males and females 
respectively. 72.4% of males were smokers and alcoholic addicts 
whereas 73.1% of females were using caffeine and betel nuts 
regularly.  
Population living status, 83.9% of the rural population was living 
highest number than the urban living population (16.1%). 
Economical status, overall 67.0% of patients had a low economic 
status, 64.3% of males and 73.1% of females. Poly pharmacy, the 
overall poly pharmacy rate was 71.1%, males and females’ 
patients 72.4%, 68.3% respectively. The mean number of poly 
pharmacy was 14.09±2.14. The Prevalence rate of hypertension 
was higher in males (89.1%) was observed during the period 
(2014–2015) while in the females it was observed as (87.8%).
Overall, 56.5% patients were regularly visited in the hospital, 53.5% 
of males and 63.4% of females. Knowledge and awareness on 
hypertension, overall 38.2% of patients had an awareness of 
hypertension, in that 28.6% of males and 59.7% of females. 
 
Overall, 56.5% study participants were regularly visited in the 
hospital, 53.5% of males and 63.4% of females. Knowledge and 
awareness on hypertension, overall 38.2% of patients had an 
awareness of hypertension, in that 28.6% of males and 59.7% of 
females. 
Overall average monthly and annual household income was 
observed to be 1T₹1259, ₹15108 respectively. Household income 
range from ₹400 to ₹10,000/month and for females and males 
average annual household income was ₹1T 3644 and 1T₹1T 7460 
respectively. In the ccupational category, overall 67.4% of laboring 
patients, 72.4% of male and 56.0% of female laboring. Therapy 
duration, overall 50.9% of hypertensive patients’ therapy duration 
in 1 ≤ 10 y a nd 60.5% of males and 29.2% of females and overall 
11.9% were early diagnosed diseases (less than 1 y). Overall, 61.8% 
of patients had multiple comorbidities in that males (66.0%) had 
higher co morbidities of (CAD+Type II DM) than females (52.4%). 
Data on socio demographic and clinical features of hypertensive 
patient’s data were given in table No.1. 
Total cost per annum of individual drug for the 267 
hypertensive patients on oral dosage forms:  
The total cost/annum of individual medication for the 267 
hypertensive patients with multiple comorbidity data were 
represented in table No.2. Among 267 hypertensive, ramipril was 
administered to 228 patients and each unit price ramipril 
was 1T₹1T6.7/and total cost per annum (ramipril) was analyzed 
that 1T₹ 1T6,524,448.0 in 2015 and total medication cost per annum 
was 1T₹ 1T 3,383,382.0/and percentage of the annual total direct cost of 
illness (medication cost) was 53.3%. On this, costs were included 
free cost components. Total free drug cost per annum was 
analyzed 1T₹1,704,112.0/in 2015 and 1Tenalapril maleate, atenolol and 
metformin drugs were specially provided for free of cost for 
hypertension with multiple comorbidities. 
  




Total drug cost 
(in %) 
(%) Annual 
direct COI  
Drug administered [No. of 
patients] 
% of patients 
administered 
Ramipril 6,524,448.0 49.0 26.0 228 85.4 
Metoprolol 1,604,394.0 12.0 6.41 198 74.1 
Amlodipine  430,590.5 3.2 1.72 251 94.0 
Telmisartan  182,573.0 1.4 0.72 61 22.8 













Nebivolol  20,440.0 0.1 0.08 56 20.9 
Furosamide  37,814.0 0.2 0.15 259 97.0 
Aspirin  19,053.0 0.1 0.07 261 97.7 
Clopidogrel  655,248.0 4.9 2.61 264 98.8 
Atorvastatin 1,305,532.0 9.8 5.21 263 98.5 
Glimipride  143,080.0 1.0 0.57 196 73.4 
Glipizide  139,430.0 1.0 0.55 191 71.5 
Total 11,679,270.00 
Free cost components 
Enalapril maleate 756,280.0 5.6 3.02 259 97.0 
Atenolol  80,592.0 0.6 0.32 92 34.4 
Metformin  867,240.0 6.5 3.45 198 74.1 
Total Free cost 1,704,112.0 12.7 6.7 
Total cost [Drugs] 13,383,382.0 100.0 53.3 
 
Nachiya et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 3, 225-230 
229 
Assessment of direct and morbidity cost 
Table No.3 demonstrated the annual direct cost analysis like 
equipment, diet, and medication cost, diagnostic/laboratory tests, 
hospitalization, personnel cost and transport cost were computed 
for hypertensive study groups. Among the study population, total 
mean value direct medical costs, direct non-medical costs, morbidity 
costs were analyzed to be ₹1,408,082.4, ₹9171.4, 
₹10,789.2 respectively. The total COI was ₹
  
27,993,470.0. Of this, the 
percentage of total cost of direct medical costs was 89.5%, 0.3% 
were direct non medical cost and 10.2% was morbidity costs. These 
are the factors were influenced cost of the hypertensive study 
population. In this study, direct costs were constituted the greatest 
cost constituent of the economical burden of illness, on the other 
hand medication cost estimates constituted the greatest constituent 
of direct medical consumptions. 
Table 3: Annual direct cost analysis of the 267 hospitalized patients in hypertension management 
Annual direct cost analysis 
COI Cost constituents Total cost/year ( Average cost (₹) % Annual direct COI ₹) % Total COI 
































Direct medical cost 25,000,322.0  1,408,082.4 99.7 89.5 
Direct non-medical Cost Transport  1,121,40.0  9171.4  0.3 0.3 
Annual direct cost  25,112,462.0  1,417,253.8 100.0 89.8 
 
Data on table No.4 were represented the annual indirect cost analysis 
like patient and caretaker’s income loss and also in this data were 
included total cost of illness. Estimation of total cost of illness is sum of 
annual direct and indirect cost analsis for hypertensive study population. 
 
Table 4: Annual Indirect and total cost of illness for the 267 hospitalized patients in hypertension management 
Annual indirect cost analysis 
COI Cost constituents Total cost/year Average cost  % Annual Indirect COI % Total COI 
Indirect non medical cost Morbidity cost 
Patient income loss 









Total (annual indirect non–medical cost)  2,881,008.0 10789.2 100.0 10.2 
Total cost of illness 27,993,470.0 100.0 
  
 
Fig. 1: Distribution of total costs of illness in hypertension care 
 
DISCUSSION 
Hypertension is a heterogeneous disorder not diseases, according 
WHO says that hypertension is a third leading killer in the world. 
Overall research study literature showing that, hypertension is one 
of the world’s largest increasing economic burden on the rural 
population. To be reducing direct costs can be achieved by changing 
lifestyle habits like reducing dietary sodium intake, decreasing body 
weight, quitting smoking and reducing alcohol intake. In addition, 
anti-hypertensive medications can lower the risk of cardiovascular 
mortality in hypertensive individuals [8]. 
Economic burden of hypertension is much affect with rural 
population than the urban population. Because, urban population 
expending more cost on hypertension care than rural population, In 
rural counterpart, not having enough knowledge, awareness on 
proper pressure monitoring and due to too much expensive, unable 
to afford on their illness due to poverty, increasing illness with 
increasing economic burden, and that poverty because of illness has 
become a significant social problem [9]. Most of the people affect 
with hypertension at the age of ≥ 65 y elderly people. Hypertension 
is an important public health challenge worldwide because of its 
high prevalence and concomitant increase in risk of disease [10]. An 
economic burden of illness study carried on the study site where 
people coming in and around from rural area.  
Regarding socioeconomic and demographic surveillance findings 
revealed some four factors: first, women (59.7%) had more 
prominent of knowledge than men (28.6%) with respect to 
awareness of hypertension. This finding is supported by other 
studies [11 & 12]. The outcome of the study, gender must be focused 
on the hypertension management also proper counseling can be 
given to male gender to improve their knowledge on hypertension. 
Second, the prevalence of hypertension, present study findings 
stated 89.7% men had more prevalence than women (87.8%). Our 
findings are in contradiction with a study conducted by Cai Le et al. 
in China, they reported 23.8% and 25.7% in men and women 
respectively. Third aspect is the therapeutic management of 
hypertension, the finding of the present study shown that women 
(63.4%) had a more prominent treatment rate on hypertension 
management than men (53.5%), which is similar to the study [12]. 
Fourth, average per annum income, concentrates on both genders 
(male and female), in that both annual income status was very poor 
and their household income not sufficient for their health 
management.  
Among the direct medical costs, procurement of medicine costs was 
constituted over 47.8%. The total direct medical cost was largest 
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cost constituents more than other costs including the morbidity 
costs. Of this amount, diagnostic/laboratory (1.0%), hospitalization 
related costs (0.3%) and transportation costs (0.3%), which are low 
direct medical cost of illness. 
Regarding average length of stay study findings revealed that, 
average length of hospitalization was 18.7 d to treat hypertension 
and multiple co-morbidities also. 67.4% of patients were staying 
more than 10 d and cost of medication was greatest constituent 
observed in this present study also only a few drugs were provided 
for free of cost components (12.7% of the total cost) to the patients 
by the hospital. Comparatively, in this study, total indirect medical 
cost was the second largest component.  
Overall drug cost is ₹13, 383,382 (47.8%) for the entire study 
patient, whereas the total cost of anti-hypertensive medications 
alone is ₹9, 416,927 (70.3%). The present study shows that total 
drug cost was less than the study conducted by Muna et al. 
(Antihypertensive medications: 83.7% of total drug costs). Based on 
the reports of the present study, ramipril alone was administered 
the cost 
The limitations of the present are: (i) study conducted in only one 
site and sample size being very small when compared with the 
hypertensive population. (ii) The present is focused on only 
inpatients, and outpatients were excluded from the analysis because 
unable to collect their registration information and not enough 
sufficient data. (iii) This study does not measure patient’s 
employment in the hospital follow-up period after patients’ re-
hospitalization. (iv) Some patients might have received medication 
during re-hospitalization; this medication would not be analyzed in 
hospitalized patient pharmacy claims. (v) Due to a less time period, 
we did not perform patient mortality cost and intangible cost of 
illness. (vi) Did not assess parenteral dosage form because they 
were administered to the very negligible portion of patients. 
₹6,524,448.0 (23.3%) of the total cost of illness. Ramipril 
has a cost/DDD of 78.4 (DDD–2.5 mg) and was prescribed for 228 
hypertensive. Total cost of anti-diabetic drugs ₹ 2, 82,510.0 (1.0%) 
and total cost of anti-platelet drugs ₹6, 74,301 (2.4%) of total cost of 
illness. Total estimation of free drug components of anti-
hypertensive drugs (Enalapril maleate+Atenolol) ₹8, 36,872 (2.9%) 
of the total cost of illness. Of this amount, enalapril maleate drug cost 
₹7, 56,280.0 (2.7%) was administered to 259 patients. The ramipril 
has been indicated that to stabilize renal function in hypertensive 
diabetics might be responsible for its high degree of usage. Screening 
of patients for those at risk of nephropathy might be beneficial as well 
as subsequent regular monitoring of their renal function [13]. Overall 
estimated that, total cost per annum, largest constituents like 
equipment cost (34.0%), diet (11.4%), Medication cost (53.3%), 
patient income loss (46.8%) and Caretaker’s income loss (53.2%) of 
annual direct and indirect cost of illness observed in the present study. 
Present, concerning personnel cost such as (Physician cost, 
pharmacist cost and nursing cost) considered as 0. Because patients 
do not spend any cost for health care professionals.  
In rural population, mainly cost is greatest affordability also they 
had a lack of awareness of their illness, poor educational status, low 
socioeconomic status, poor monitoring on their complications and 
irregular treatment. These all the factors were influencing patients’ 
lack of quality of care and to increase hypertensive complications. 
The clinical pharmacist in collaboration with other health care 
professionals’ main important key role is, to give awareness on 
hypertension complications, proper monitoring blood pressure, 
consult with a physician regularly and special care to be given to 
rural population, prevention of hypertensive complications and can 
be improved the quality of hypertension care. 
Study limitations 
CONCLUSION 
Our finding indicates that, total direct cost components were 
incurred higher than the other components, which was increasing 
the treatment burden for hypertension patients.  
Hypertension leads to the economic burden in economically low 
patients from rural. The findings of the present study revealed that 
the direct medical cost is more which directly cause impact while 
purchasing the medicines. The patients are reluctant to purchase the 
medicines and not adhering to their therapeutic regimen. Our 
recommendation is to distribute low cost medicines at free of cost to 
the economy low segment of patients. 
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